CAS NO: | 331731-18-1 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
25mg | 电议 |
50mg | 电议 |
生物活性 | Adalimumab is a human monoclonalIgG1antibody targeting tumour necrosis factor α (TNF-α). |
IC50& Target | TNF-α[1] |
体外研究 (In Vitro) | Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study[2]. |
体内研究 (In Vivo) | The elimination half-life (t1/2) of Adalimumab is long (~20 days)[1]. The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr-/-mice[2]. |
Clinical Trial | |
分子量 | 145425.42 |
性状 | Liquid |
CAS 号 | 331731-18-1 |
中文名称 | 阿达木单抗;阿达莫单抗 |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |